COVID-19 Burden on HIV Patients Attending Antiretroviral Therapy in Addis Ababa, Ethiopia: A Multicenter

Dagmawi Chilot1,2, Yimtubezinash Woldeamanuel1, Tsegahun Manyazewal1

  • 1Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

Frontiers in Medicine
|March 21, 2022
PubMed

Insights

The COVID-19 pandemic significantly disrupted HIV care in Ethiopia, leading to missed appointments for medication refills and follow-ups. Fear of COVID-19, transport issues, and reduced income were key barriers for patients on antiretroviral therapy.

Area of Science:

  • Public Health
  • Infectious Diseases
  • HIV/AIDS Management

Background:

  • Ethiopia has made progress in HIV screening, testing, and retention.
  • Concerns exist about COVID-19 disrupting HIV programs, potentially increasing mortality and new infections.
  • This study investigated the impact of COVID-19 on patients receiving antiretroviral therapy (ART).

Purpose of the Study:

  • To assess the real-time burden of COVID-19 on HIV-positive patients undergoing antiretroviral therapy.
  • To identify factors contributing to missed appointments and follow-up services during the pandemic.

Main Methods:

  • A multicenter, cross-sectional study was conducted in 10 healthcare facilities in Addis Ababa, Ethiopia.
  • Data were collected from 212 HIV-positive patients using interviewer-based questionnaires.
  • Statistical analysis was performed using SPSS version 26.

Main Results:

  • 27.4% of patients missed medication refill appointments, with predictors including age ≥ 55, fear of COVID-19, transport disruption, reduced income, and limited access to masks.
  • 26.4% missed diagnostic tests, influenced by age, partial lockdown, limited health service access, reduced income, and mask availability.
  • 25.9% missed counseling services, with significant predictors being age ≥ 55, fear of COVID-19, reduced income, mask availability, and partial lockdown.

Conclusions:

  • COVID-19 significantly burdened HIV patients' ability to attend routine clinical care and treatment.
  • Missed appointments for refills, clinical, and laboratory follow-ups may lead to treatment failure and drug resistance.
  • Targeted initiatives are crucial to sustain HIV care and improve the well-being of people living with HIV.
Abstract

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
347
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
47.2K
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
438
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
483
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
493
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
258